ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 677 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Mr. Adam Grossman is the President of ADMA Biologics Inc, joining the firm since 2007.
What is the price performance of ADMA stock?
The current price of ADMA is $15.89, it has increased 0.37% in the last trading day.
What are the primary business themes or industries for ADMA Biologics Inc?
ADMA Biologics Inc belongs to Biotechnology industry and the sector is Health Care
What is ADMA Biologics Inc market cap?
ADMA Biologics Inc's current market cap is $3.7B
Is ADMA Biologics Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for ADMA Biologics Inc, including 3 strong buy, 5 buy, 2 hold, 0 sell, and 3 strong sell